福泰製藥 VRTX 深 滬
等待開盤 12-17 09:30:00 美东时间
454.96
-0.750
-0.16%
華盛通- 最 高459.00
- 今 開455.71
- 成交量 113.73万股
- 最 低 452.83
- 昨 收 455.71
- 總市值 1155.60亿
- 52周最高 519.68
- 市盈率 靜 --
- 換手率 0.45%
- 52周最低 362.50
- 委 比 98.16%
- 總股本 2.54亿
- 歷史最高 519.88
- 量 比 0.93
- 振 幅 1.35%
- 歷史最低 26.50
- 每 手 1
- 風險率 36.28%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 超配！大摩上调回声星通信评级；汽车地带、CBRL、金宝汤、家得宝等遭多家大行下调目标价
今日重点评级关注：Ascendiant Capital：维持Lucid Diagnostics"买入"评级，目标价从8美元升至8.25美元；Ascendiant Capital：维持Aytu BioPharma"买入"评级，目标价从12.5美元升至13美元
12-11 10:33
Wells Fargo Maintains Overweight on Vertex Pharmaceuticals, Raises Price Target to $515
Wells Fargo analyst Mohit Bansal maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Overweight and raises the price target from $460 to $515.
12-11 04:08
Disney, Nu Holdings, Phillips 66 And A Health Care Stock On CNBC's 'Final Trades'
Nu Holdings, Phillips 66, Vertex Pharmaceuticals and Disney get shoutouts on CNBC's "Halftime Report Final Trades."
12-08 23:44
Vertex's Gene Therapy Works In Children With Blood Disorders
Vertex Pharmaceuticals presents clinical data demonstrating benefits of Casgevy in SCD and TDT patients aged 5+ at ASH meeting.
12-08 21:17
美股大行评级 | 高盛上调梅西百货目标价至22美元！ 摩根大通上调美国铝业公司目标价至45美元
今日重点评级关注：Stifel：维持X4 Pharmaceuticals"买入"评级，目标价从7.5美元升至10美元；花旗：维持UP Fintech Holding"买入"评级，目标价从17.4美元升至17.5美元
12-08 08:34
美股大行评级 | 美鹰服饰、CrowdStrike、迈威尔科技获多家机构上调目标价；ACHC、GitLab、Okta遭多家机构下调目标价
今日重点评级关注：Guggenheim：维持Cybin Inc. Common Shares"买入"评级，目标价从39美元升至48美元；HC Wainwright & Co.：维持Capricor Therapeutics"买入"评级，目标价从24美元升至60美元
12-04 09:38
Morgan Stanley Upgrades Vertex Pharmaceuticals to Overweight, Raises Price Target to $516
Morgan Stanley analyst Terence Flynn upgrades Vertex Pharmaceuticals (NASDAQ:VRTX) from Equal-Weight to Overweight and raises the price target from $438 to $516.
12-03 23:35
Is Vertex Pharmaceuticals Inc Gaining or Losing Market Support?
Vertex Pharmaceuticals Inc's (NYSE:VRTX) short interest as a percent of float h...
11-18 04:00
Vertex highlights growing Medicaid coverage for non-opioid painkiller Journavx
Vertex Pharmaceuticals CEO Reshma Kewalramani said that the company has gained Medicaid coverage approval for its non-opioid pain drug Journavx (suzetrigine) in 18 states. Speaking at the UBS Global H...
11-12 02:01
